Treatment-associated side effects can have a significant impact on patient quality of life and treatment adherence. In the context of a life-long medical condition such as IBD, addressing potential tolerability issues becomes even more critical.

giiant pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision delivery remains a central focus for the development of new drug therapeutics, with limited systemic exposure for a safer profile while maximizing local action to improve IBD patient care.

giiant pharma‘s GastroIntestinal-Induced ANTi-inflammatory technology is a uniquely targeted delivery strategy, developed by two former Merck Frosst scientists, using the bacterial activity of the gut microbiota to bioactivate and release the active drug substance at specific locations in the lower GI tract.

Although orally-delivered, giiant’s drug candidates are not systemically absorbed but remain able to achieve high drug concentrations in the colonic area.

giiant pharma aims to become a GI leader in precision delivery technologies, with the ability to develop safer, patient-tailored drug therapeutics with local, tissue-specific delivery or bioactivation. These efforts should provide optimal treatment modalities to patients for various GI diseases and conditions.

giiant pharma Inc is a Montreal-based biotech company, founded by two former Merck Frosst scientists, and repeat entrepreneurs with a significant depth of expertise in the area of Gastrointestinal drug development. Guided by the concept of Precision Delivery and using its proprietary GastroIntestinal-Induced ANti-inflammatory Technology (GIIANT) the company has developed its lead program GT-2108 for the treatment of moderate-to-severe ulcerative colitis. This approach capitalizes on the enzymatic activity of the colon microbiota to bioactivate the prodrug of phosphodiestherase-4 (PDE4) inhibitor and specifically release the active moiety at the site of inflammation.